

Global Tumor Biomarker Testing Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G85C07B3C702EN.html>

Date: May 2026

Pages: 217

Price: US\$ 3,660.00 (Single User License)

ID: G85C07B3C702EN

Abstracts

The global Tumor Biomarker Testing market size is predicted to grow from US\$ 11837 million in 2025 to US\$ 24467 million in 2032; it is expected to grow at a CAGR of 11.1% from 2026 to 2032.

Tumor Biomarker Testing refers to the broad category of diagnostic products and testing services used to analyze measurable features associated with malignant tumors for diagnosis, classification, therapy selection, treatment monitoring, recurrence surveillance, and prognosis assessment. The analytes covered by Tumor Biomarker Testing may include protein markers, DNA mutations, RNA fusions, copy number variations, methylation signatures, microsatellite instability, tumor mutational burden, PD-L1 expression, circulating tumor DNA, and circulating tumor cells in tissue, blood, bone marrow, cells, or other body fluid samples. In commercial form, Tumor Biomarker Testing may appear as central-laboratory testing services, PCR kits, NGS panels, IHC/ISH reagents, cartridge-based automated systems, quality controls, and integrated software-reporting solutions. Its structure usually includes sample collection and preservation media, pre-analytical reagents, amplification or hybridization chemistry, signal detection instruments, bioinformatics interpretation modules, and clinical reporting. The core principle is to convert reproducible molecular or cellular abnormalities of cancer into clinically actionable information.

The growth of Tumor Biomarker Testing is fundamentally supported by the rising global cancer burden and the deeper penetration of precision oncology. With around 20 million new cancer cases worldwide in 2022 and a continued shift toward targeted therapy, immunotherapy, and biomarker-guided treatment, clinical practice is moving from single-gene testing toward comprehensive biomarker testing and comprehensive genomic profiling. Guideline adoption and expanding drug-label linkage are driving demand for

tissue testing, liquid biopsy, companion diagnostics, and MRD monitoring.

The major restraints remain access, reimbursement, standardization, and real-world implementation efficiency. Many patients still do not receive complete biomarker testing early enough in the treatment pathway, while tissue inadequacy, workflow fragmentation, inter-laboratory variability, low-shedding ctDNA, result interpretation complexity, and uneven payment coverage continue to limit adoption. For suppliers, regulatory compliance, evidence generation, quality systems, and secure data handling raise barriers to scale.

Downstream demand is shifting from one-time testing toward longitudinal, multi-sample, and multi-technology testing. Hospitals increasingly prefer integrated solutions that cover DNA, RNA, protein, and immune-related markers with faster turnaround and less tissue consumption. Advanced solid tumor care is moving toward broader pan-cancer panels and liquid biopsy, while post-surgical and treatment-monitoring settings are accelerating demand for ctDNA-MRD and recurrence surveillance. As a result, decentralized cartridge systems and centralized high-complexity genomic labs will continue to coexist, serving different clinical needs.

LPI (LP Information)' newest research report, the 'Tumor Biomarker Testing Industry Forecast' looks at past sales and reviews total world Tumor Biomarker Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Tumor Biomarker Testing sales for 2026 through 2032. With Tumor Biomarker Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Tumor Biomarker Testing industry.

This Insight Report provides a comprehensive analysis of the global Tumor Biomarker Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Tumor Biomarker Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tumor Biomarker Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Biomarker Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced

view of the current state and future trajectory in the global Tumor Biomarker Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Biomarker Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:

DNA Biomarker Testing

RNA Biomarker Testing

Protein Biomarker Testing

Cell-based Biomarker Testing

Multi-analyte Biomarker Testing

Segmentation by Sample Source:

Tissue-based Testing

Blood-based Testing

Bone Marrow-based Testing

Other Body Fluid-based Testing

Segmentation by Delivery Model:

Central Laboratory Testing

Hospital In-house Testing

Segmentation by Detection Technology:

Sequencing-based Testing

PCR-based Testing

Immunoassay-based Testing

Hybridization-based Testing

Cell Analysis-based Testing

Segmentation by Application:

Lung Cancer

Breast Cancer

Colorectal

Prostate Cancer

Blood Cancer

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Abbott Laboratories

Agilent Technologies

Roche

Thermo Fisher Scientific

QIAGEN

Illumina

DiaSorin

Fujirebio

Siemens Healthineers

Quest Diagnostics

Labcorp

NeoGenomics

Exact Sciences

Myriad Genetics

Guardant Health

Caris Life Sciences

Tempus AI

Natera

Personalis

Invivoscribe

Biocartis

Sysmex

Leica Biosystems

Cepheid

Menarini Silicon Biosystems

Veracyte

Castle Biosciences

OncoDNA

ACT Genomics

GC Genome

Burning Rock

Amoy Diagnostics

Genetron Health

3DMed Diagnostics

Singlera Genomics

BGI Genomics

Geneseeq

Genecast

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Tumor Biomarker Testing Market Size (2021-2032)
 - 2.1.2 Tumor Biomarker Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Tumor Biomarker Testing by Country/Region (2021, 2025 & 2032)
- 2.2 Tumor Biomarker Testing Segment by Type
 - 2.2.1 DNA Biomarker Testing
 - 2.2.2 RNA Biomarker Testing
 - 2.2.3 Protein Biomarker Testing
 - 2.2.4 Cell-based Biomarker Testing
 - 2.2.5 Multi-analyte Biomarker Testing
 - 2.2.6 Tumor Biomarker Testing Market Size by Type
 - 2.2.6.1 Tumor Biomarker Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.6.2 Global Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
- 2.3 Tumor Biomarker Testing Segment by Sample Source
 - 2.3.1 Tissue-based Testing
 - 2.3.2 Blood-based Testing
 - 2.3.3 Bone Marrow-based Testing
 - 2.3.4 Other Body Fluid-based Testing
 - 2.3.5 Tumor Biomarker Testing Market Size by Sample Source
 - 2.3.5.1 Tumor Biomarker Testing Market Size CAGR by Sample Source (2021 VS

2025 VS 2032)

2.3.5.2 Global Tumor Biomarker Testing Market Size Market Share by Sample

Source (2021-2026)

2.4 Tumor Biomarker Testing Segment by Delivery Model

2.4.1 Central Laboratory Testing

2.4.2 Hospital In-house Testing

2.4.3 Tumor Biomarker Testing Market Size by Delivery Model

2.4.3.1 Tumor Biomarker Testing Market Size CAGR by Delivery Model (2021 VS 2025 VS 2032)

2.4.3.2 Global Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2026)

2.5 Tumor Biomarker Testing Segment by Detection Technology

2.5.1 Sequencing-based Testing

2.5.2 PCR-based Testing

2.5.3 Immunoassay-based Testing

2.5.4 Hybridization-based Testing

2.5.5 Cell Analysis-based Testing

2.5.6 Tumor Biomarker Testing Market Size by Detection Technology

2.5.6.1 Tumor Biomarker Testing Market Size CAGR by Detection Technology (2021 VS 2025 VS 2032)

2.5.6.2 Global Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2026)

2.6 Tumor Biomarker Testing Segment by Application

2.6.1 Lung Cancer

2.6.2 Breast Cancer

2.6.3 Colorectal

2.6.4 Prostate Cancer

2.6.5 Blood Cancer

2.6.6 Tumor Biomarker Testing Market Size by Application

2.6.6.1 Tumor Biomarker Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.6.6.2 Global Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)

3 TUMOR BIOMARKER TESTING MARKET SIZE BY PLAYER

3.1 Tumor Biomarker Testing Market Size Market Share by Player

3.1.1 Global Tumor Biomarker Testing Revenue by Player (2021-2026)

3.1.2 Global Tumor Biomarker Testing Revenue Market Share by Player (2021-2026)

3.2 Global Tumor Biomarker Testing Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 TUMOR BIOMARKER TESTING BY REGION

4.1 Tumor Biomarker Testing Market Size by Region (2021-2026)

4.2 Global Tumor Biomarker Testing Annual Revenue by Country/Region (2021-2026)

4.3 Americas Tumor Biomarker Testing Market Size Growth (2021-2026)

4.4 APAC Tumor Biomarker Testing Market Size Growth (2021-2026)

4.5 Europe Tumor Biomarker Testing Market Size Growth (2021-2026)

4.6 Middle East & Africa Tumor Biomarker Testing Market Size Growth (2021-2026)

5 AMERICAS

5.1 Americas Tumor Biomarker Testing Market Size by Country (2021-2026)

5.2 Americas Tumor Biomarker Testing Market Size by Type (2021-2026)

5.3 Americas Tumor Biomarker Testing Market Size by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Tumor Biomarker Testing Market Size by Region (2021-2026)

6.2 APAC Tumor Biomarker Testing Market Size by Type (2021-2026)

6.3 APAC Tumor Biomarker Testing Market Size by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

- 7.1 Europe Tumor Biomarker Testing Market Size by Country (2021-2026)
- 7.2 Europe Tumor Biomarker Testing Market Size by Type (2021-2026)
- 7.3 Europe Tumor Biomarker Testing Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Tumor Biomarker Testing by Region (2021-2026)
- 8.2 Middle East & Africa Tumor Biomarker Testing Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Tumor Biomarker Testing Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL TUMOR BIOMARKER TESTING MARKET FORECAST

- 10.1 Global Tumor Biomarker Testing Forecast by Region (2027-2032)
 - 10.1.1 Global Tumor Biomarker Testing Forecast by Region (2027-2032)
 - 10.1.2 Americas Tumor Biomarker Testing Forecast
 - 10.1.3 APAC Tumor Biomarker Testing Forecast
 - 10.1.4 Europe Tumor Biomarker Testing Forecast
 - 10.1.5 Middle East & Africa Tumor Biomarker Testing Forecast
- 10.2 Americas Tumor Biomarker Testing Forecast by Country (2027-2032)
 - 10.2.1 United States Market Tumor Biomarker Testing Forecast
 - 10.2.2 Canada Market Tumor Biomarker Testing Forecast

- 10.2.3 Mexico Market Tumor Biomarker Testing Forecast
- 10.2.4 Brazil Market Tumor Biomarker Testing Forecast
- 10.3 APAC Tumor Biomarker Testing Forecast by Region (2027-2032)
 - 10.3.1 China Tumor Biomarker Testing Market Forecast
 - 10.3.2 Japan Market Tumor Biomarker Testing Forecast
 - 10.3.3 Korea Market Tumor Biomarker Testing Forecast
 - 10.3.4 Southeast Asia Market Tumor Biomarker Testing Forecast
 - 10.3.5 India Market Tumor Biomarker Testing Forecast
 - 10.3.6 Australia Market Tumor Biomarker Testing Forecast
- 10.4 Europe Tumor Biomarker Testing Forecast by Country (2027-2032)
 - 10.4.1 Germany Market Tumor Biomarker Testing Forecast
 - 10.4.2 France Market Tumor Biomarker Testing Forecast
 - 10.4.3 UK Market Tumor Biomarker Testing Forecast
 - 10.4.4 Italy Market Tumor Biomarker Testing Forecast
 - 10.4.5 Russia Market Tumor Biomarker Testing Forecast
- 10.5 Middle East & Africa Tumor Biomarker Testing Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Tumor Biomarker Testing Forecast
 - 10.5.2 South Africa Market Tumor Biomarker Testing Forecast
 - 10.5.3 Israel Market Tumor Biomarker Testing Forecast
 - 10.5.4 Turkey Market Tumor Biomarker Testing Forecast
- 10.6 Global Tumor Biomarker Testing Forecast by Type (2027-2032)
- 10.7 Global Tumor Biomarker Testing Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Tumor Biomarker Testing Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Abbott Laboratories
 - 11.1.1 Abbott Laboratories Company Information
 - 11.1.2 Abbott Laboratories Tumor Biomarker Testing Product Offered
 - 11.1.3 Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.1.4 Abbott Laboratories Main Business Overview
 - 11.1.5 Abbott Laboratories Latest Developments
- 11.2 Agilent Technologies
 - 11.2.1 Agilent Technologies Company Information
 - 11.2.2 Agilent Technologies Tumor Biomarker Testing Product Offered
 - 11.2.3 Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.2.4 Agilent Technologies Main Business Overview

- 11.2.5 Agilent Technologies Latest Developments
- 11.3 Roche
 - 11.3.1 Roche Company Information
 - 11.3.2 Roche Tumor Biomarker Testing Product Offered
 - 11.3.3 Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.3.4 Roche Main Business Overview
 - 11.3.5 Roche Latest Developments
- 11.4 Thermo Fisher Scientific
 - 11.4.1 Thermo Fisher Scientific Company Information
 - 11.4.2 Thermo Fisher Scientific Tumor Biomarker Testing Product Offered
 - 11.4.3 Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.4.4 Thermo Fisher Scientific Main Business Overview
 - 11.4.5 Thermo Fisher Scientific Latest Developments
- 11.5 QIAGEN
 - 11.5.1 QIAGEN Company Information
 - 11.5.2 QIAGEN Tumor Biomarker Testing Product Offered
 - 11.5.3 QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.5.4 QIAGEN Main Business Overview
 - 11.5.5 QIAGEN Latest Developments
- 11.6 Illumina
 - 11.6.1 Illumina Company Information
 - 11.6.2 Illumina Tumor Biomarker Testing Product Offered
 - 11.6.3 Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Illumina Main Business Overview
 - 11.6.5 Illumina Latest Developments
- 11.7 DiaSorin
 - 11.7.1 DiaSorin Company Information
 - 11.7.2 DiaSorin Tumor Biomarker Testing Product Offered
 - 11.7.3 DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 DiaSorin Main Business Overview
 - 11.7.5 DiaSorin Latest Developments
- 11.8 Fujirebio
 - 11.8.1 Fujirebio Company Information
 - 11.8.2 Fujirebio Tumor Biomarker Testing Product Offered

- 11.8.3 Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 Fujirebio Main Business Overview
 - 11.8.5 Fujirebio Latest Developments
- 11.9 Siemens Healthineers
 - 11.9.1 Siemens Healthineers Company Information
 - 11.9.2 Siemens Healthineers Tumor Biomarker Testing Product Offered
 - 11.9.3 Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 Siemens Healthineers Main Business Overview
 - 11.9.5 Siemens Healthineers Latest Developments
- 11.10 Quest Diagnostics
 - 11.10.1 Quest Diagnostics Company Information
 - 11.10.2 Quest Diagnostics Tumor Biomarker Testing Product Offered
 - 11.10.3 Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.10.4 Quest Diagnostics Main Business Overview
 - 11.10.5 Quest Diagnostics Latest Developments
- 11.11 Labcorp
 - 11.11.1 Labcorp Company Information
 - 11.11.2 Labcorp Tumor Biomarker Testing Product Offered
 - 11.11.3 Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.11.4 Labcorp Main Business Overview
 - 11.11.5 Labcorp Latest Developments
- 11.12 NeoGenomics
 - 11.12.1 NeoGenomics Company Information
 - 11.12.2 NeoGenomics Tumor Biomarker Testing Product Offered
 - 11.12.3 NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.12.4 NeoGenomics Main Business Overview
 - 11.12.5 NeoGenomics Latest Developments
- 11.13 Exact Sciences
 - 11.13.1 Exact Sciences Company Information
 - 11.13.2 Exact Sciences Tumor Biomarker Testing Product Offered
 - 11.13.3 Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.13.4 Exact Sciences Main Business Overview
 - 11.13.5 Exact Sciences Latest Developments

11.14 Myriad Genetics

11.14.1 Myriad Genetics Company Information

11.14.2 Myriad Genetics Tumor Biomarker Testing Product Offered

11.14.3 Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

11.14.4 Myriad Genetics Main Business Overview

11.14.5 Myriad Genetics Latest Developments

11.15 Guardant Health

11.15.1 Guardant Health Company Information

11.15.2 Guardant Health Tumor Biomarker Testing Product Offered

11.15.3 Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

11.15.4 Guardant Health Main Business Overview

11.15.5 Guardant Health Latest Developments

11.16 Caris Life Sciences

11.16.1 Caris Life Sciences Company Information

11.16.2 Caris Life Sciences Tumor Biomarker Testing Product Offered

11.16.3 Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

11.16.4 Caris Life Sciences Main Business Overview

11.16.5 Caris Life Sciences Latest Developments

11.17 Tempus AI

11.17.1 Tempus AI Company Information

11.17.2 Tempus AI Tumor Biomarker Testing Product Offered

11.17.3 Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

11.17.4 Tempus AI Main Business Overview

11.17.5 Tempus AI Latest Developments

11.18 Natera

11.18.1 Natera Company Information

11.18.2 Natera Tumor Biomarker Testing Product Offered

11.18.3 Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

11.18.4 Natera Main Business Overview

11.18.5 Natera Latest Developments

11.19 Personalis

11.19.1 Personalis Company Information

11.19.2 Personalis Tumor Biomarker Testing Product Offered

11.19.3 Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market

Share (2021-2026)

11.19.4 Personalis Main Business Overview

11.19.5 Personalis Latest Developments

11.20 Invivoscribe

11.20.1 Invivoscribe Company Information

11.20.2 Invivoscribe Tumor Biomarker Testing Product Offered

11.20.3 Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market

Share (2021-2026)

11.20.4 Invivoscribe Main Business Overview

11.20.5 Invivoscribe Latest Developments

11.21 Biocartis

11.21.1 Biocartis Company Information

11.21.2 Biocartis Tumor Biomarker Testing Product Offered

11.21.3 Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

11.21.4 Biocartis Main Business Overview

11.21.5 Biocartis Latest Developments

11.22 Sysmex

11.22.1 Sysmex Company Information

11.22.2 Sysmex Tumor Biomarker Testing Product Offered

11.22.3 Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

11.22.4 Sysmex Main Business Overview

11.22.5 Sysmex Latest Developments

11.23 Leica Biosystems

11.23.1 Leica Biosystems Company Information

11.23.2 Leica Biosystems Tumor Biomarker Testing Product Offered

11.23.3 Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and

Market Share (2021-2026)

11.23.4 Leica Biosystems Main Business Overview

11.23.5 Leica Biosystems Latest Developments

11.24 Cepheid

11.24.1 Cepheid Company Information

11.24.2 Cepheid Tumor Biomarker Testing Product Offered

11.24.3 Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share

(2021-2026)

11.24.4 Cepheid Main Business Overview

11.24.5 Cepheid Latest Developments

11.25 Menarini Silicon Biosystems

- 11.25.1 Menarini Silicon Biosystems Company Information
- 11.25.2 Menarini Silicon Biosystems Tumor Biomarker Testing Product Offered
- 11.25.3 Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 11.25.4 Menarini Silicon Biosystems Main Business Overview
- 11.25.5 Menarini Silicon Biosystems Latest Developments
- 11.26 Veracyte
 - 11.26.1 Veracyte Company Information
 - 11.26.2 Veracyte Tumor Biomarker Testing Product Offered
 - 11.26.3 Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.26.4 Veracyte Main Business Overview
 - 11.26.5 Veracyte Latest Developments
- 11.27 Castle Biosciences
 - 11.27.1 Castle Biosciences Company Information
 - 11.27.2 Castle Biosciences Tumor Biomarker Testing Product Offered
 - 11.27.3 Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.27.4 Castle Biosciences Main Business Overview
 - 11.27.5 Castle Biosciences Latest Developments
- 11.28 OncoDNA
 - 11.28.1 OncoDNA Company Information
 - 11.28.2 OncoDNA Tumor Biomarker Testing Product Offered
 - 11.28.3 OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.28.4 OncoDNA Main Business Overview
 - 11.28.5 OncoDNA Latest Developments
- 11.29 ACT Genomics
 - 11.29.1 ACT Genomics Company Information
 - 11.29.2 ACT Genomics Tumor Biomarker Testing Product Offered
 - 11.29.3 ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.29.4 ACT Genomics Main Business Overview
 - 11.29.5 ACT Genomics Latest Developments
- 11.30 GC Genome
 - 11.30.1 GC Genome Company Information
 - 11.30.2 GC Genome Tumor Biomarker Testing Product Offered
 - 11.30.3 GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)

- 11.30.4 GC Genome Main Business Overview
- 11.30.5 GC Genome Latest Developments
- 11.31 Burning Rock
 - 11.31.1 Burning Rock Company Information
 - 11.31.2 Burning Rock Tumor Biomarker Testing Product Offered
 - 11.31.3 Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.31.4 Burning Rock Main Business Overview
 - 11.31.5 Burning Rock Latest Developments
- 11.32 Amoy Diagnostics
 - 11.32.1 Amoy Diagnostics Company Information
 - 11.32.2 Amoy Diagnostics Tumor Biomarker Testing Product Offered
 - 11.32.3 Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.32.4 Amoy Diagnostics Main Business Overview
 - 11.32.5 Amoy Diagnostics Latest Developments
- 11.33 Genetron Health
 - 11.33.1 Genetron Health Company Information
 - 11.33.2 Genetron Health Tumor Biomarker Testing Product Offered
 - 11.33.3 Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.33.4 Genetron Health Main Business Overview
 - 11.33.5 Genetron Health Latest Developments
- 11.34 3DMed Diagnostics
 - 11.34.1 3DMed Diagnostics Company Information
 - 11.34.2 3DMed Diagnostics Tumor Biomarker Testing Product Offered
 - 11.34.3 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.34.4 3DMed Diagnostics Main Business Overview
 - 11.34.5 3DMed Diagnostics Latest Developments
- 11.35 Singlera Genomics
 - 11.35.1 Singlera Genomics Company Information
 - 11.35.2 Singlera Genomics Tumor Biomarker Testing Product Offered
 - 11.35.3 Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.35.4 Singlera Genomics Main Business Overview
 - 11.35.5 Singlera Genomics Latest Developments
- 11.36 BGI Genomics
 - 11.36.1 BGI Genomics Company Information

- 11.36.2 BGI Genomics Tumor Biomarker Testing Product Offered
- 11.36.3 BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
- 11.36.4 BGI Genomics Main Business Overview
- 11.36.5 BGI Genomics Latest Developments
- 11.37 Geneseeq
 - 11.37.1 Geneseeq Company Information
 - 11.37.2 Geneseeq Tumor Biomarker Testing Product Offered
 - 11.37.3 Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.37.4 Geneseeq Main Business Overview
 - 11.37.5 Geneseeq Latest Developments
- 11.38 Genecast
 - 11.38.1 Genecast Company Information
 - 11.38.2 Genecast Tumor Biomarker Testing Product Offered
 - 11.38.3 Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
 - 11.38.4 Genecast Main Business Overview
 - 11.38.5 Genecast Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Tumor Biomarker Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Tumor Biomarker Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of DNA Biomarker Testing

Table 4. Major Players of RNA Biomarker Testing

Table 5. Major Players of Protein Biomarker Testing

Table 6. Major Players of Cell-based Biomarker Testing

Table 7. Major Players of Multi-analyte Biomarker Testing

Table 8. Tumor Biomarker Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 9. Global Tumor Biomarker Testing Market Size by Type (2021-2026) & (\$ millions)

Table 10. Global Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)

Table 11. Major Players of Tissue-based Testing

Table 12. Major Players of Blood-based Testing

Table 13. Major Players of Bone Marrow-based Testing

Table 14. Major Players of Other Body Fluid-based Testing

Table 15. Tumor Biomarker Testing Market Size CAGR by Sample Source (2021 VS 2025 VS 2032) & (\$ millions)

Table 16. Global Tumor Biomarker Testing Market Size by Sample Source (2021-2026) & (\$ millions)

Table 17. Global Tumor Biomarker Testing Market Size Market Share by Sample Source (2021-2026)

Table 18. Major Players of Central Laboratory Testing

Table 19. Major Players of Hospital In-house Testing

Table 20. Tumor Biomarker Testing Market Size CAGR by Delivery Model (2021 VS 2025 VS 2032) & (\$ millions)

Table 21. Global Tumor Biomarker Testing Market Size by Delivery Model (2021-2026) & (\$ millions)

Table 22. Global Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2026)

Table 23. Major Players of Sequencing-based Testing

Table 24. Major Players of PCR-based Testing

Table 25. Major Players of Immunoassay-based Testing

Table 26. Major Players of Hybridization-based Testing

Table 27. Major Players of Cell Analysis-based Testing

Table 28. Tumor Biomarker Testing Market Size CAGR by Detection Technology (2021 VS 2025 VS 2032) & (\$ millions)

Table 29. Global Tumor Biomarker Testing Market Size by Detection Technology (2021-2026) & (\$ millions)

Table 30. Global Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2026)

Table 31. Tumor Biomarker Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 32. Global Tumor Biomarker Testing Market Size by Application (2021-2026) & (\$ millions)

Table 33. Global Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)

Table 34. Global Tumor Biomarker Testing Revenue by Player (2021-2026) & (\$ millions)

Table 35. Global Tumor Biomarker Testing Revenue Market Share by Player (2021-2026)

Table 36. Tumor Biomarker Testing Key Players Head office and Products Offered

Table 37. Tumor Biomarker Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 38. New Products and Potential Entrants

Table 39. Mergers & Acquisitions, Expansion

Table 40. Global Tumor Biomarker Testing Market Size by Region (2021-2026) & (\$ millions)

Table 41. Global Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)

Table 42. Global Tumor Biomarker Testing Revenue by Country/Region (2021-2026) & (\$ millions)

Table 43. Global Tumor Biomarker Testing Revenue Market Share by Country/Region (2021-2026)

Table 44. Americas Tumor Biomarker Testing Market Size by Country (2021-2026) & (\$ millions)

Table 45. Americas Tumor Biomarker Testing Market Size Market Share by Country (2021-2026)

Table 46. Americas Tumor Biomarker Testing Market Size by Type (2021-2026) & (\$ millions)

Table 47. Americas Tumor Biomarker Testing Market Size Market Share by Type

(2021-2026)

Table 48. Americas Tumor Biomarker Testing Market Size by Application (2021-2026) & (\$ millions)

Table 49. Americas Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)

Table 50. APAC Tumor Biomarker Testing Market Size by Region (2021-2026) & (\$ millions)

Table 51. APAC Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)

Table 52. APAC Tumor Biomarker Testing Market Size by Type (2021-2026) & (\$ millions)

Table 53. APAC Tumor Biomarker Testing Market Size by Application (2021-2026) & (\$ millions)

Table 54. Europe Tumor Biomarker Testing Market Size by Country (2021-2026) & (\$ millions)

Table 55. Europe Tumor Biomarker Testing Market Size Market Share by Country (2021-2026)

Table 56. Europe Tumor Biomarker Testing Market Size by Type (2021-2026) & (\$ millions)

Table 57. Europe Tumor Biomarker Testing Market Size by Application (2021-2026) & (\$ millions)

Table 58. Middle East & Africa Tumor Biomarker Testing Market Size by Region (2021-2026) & (\$ millions)

Table 59. Middle East & Africa Tumor Biomarker Testing Market Size by Type (2021-2026) & (\$ millions)

Table 60. Middle East & Africa Tumor Biomarker Testing Market Size by Application (2021-2026) & (\$ millions)

Table 61. Key Market Drivers & Growth Opportunities of Tumor Biomarker Testing

Table 62. Key Market Challenges & Risks of Tumor Biomarker Testing

Table 63. Key Industry Trends of Tumor Biomarker Testing

Table 64. Global Tumor Biomarker Testing Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 65. Global Tumor Biomarker Testing Market Size Market Share Forecast by Region (2027-2032)

Table 66. Global Tumor Biomarker Testing Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 67. Global Tumor Biomarker Testing Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 68. Abbott Laboratories Details, Company Type, Tumor Biomarker Testing Area

Served and Its Competitors

Table 69. Abbott Laboratories Tumor Biomarker Testing Product Offered

Table 70. Abbott Laboratories Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 71. Abbott Laboratories Main Business

Table 72. Abbott Laboratories Latest Developments

Table 73. Agilent Technologies Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 74. Agilent Technologies Tumor Biomarker Testing Product Offered

Table 75. Agilent Technologies Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 76. Agilent Technologies Main Business

Table 77. Agilent Technologies Latest Developments

Table 78. Roche Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 79. Roche Tumor Biomarker Testing Product Offered

Table 80. Roche Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 81. Roche Main Business

Table 82. Roche Latest Developments

Table 83. Thermo Fisher Scientific Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 84. Thermo Fisher Scientific Tumor Biomarker Testing Product Offered

Table 85. Thermo Fisher Scientific Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 86. Thermo Fisher Scientific Main Business

Table 87. Thermo Fisher Scientific Latest Developments

Table 88. QIAGEN Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 89. QIAGEN Tumor Biomarker Testing Product Offered

Table 90. QIAGEN Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 91. QIAGEN Main Business

Table 92. QIAGEN Latest Developments

Table 93. Illumina Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 94. Illumina Tumor Biomarker Testing Product Offered

Table 95. Illumina Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 96. Illumina Main Business

Table 97. Illumina Latest Developments

Table 98. DiaSorin Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 99. DiaSorin Tumor Biomarker Testing Product Offered

Table 100. DiaSorin Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 101. DiaSorin Main Business

Table 102. DiaSorin Latest Developments

Table 103. Fujirebio Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 104. Fujirebio Tumor Biomarker Testing Product Offered

Table 105. Fujirebio Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 106. Fujirebio Main Business

Table 107. Fujirebio Latest Developments

Table 108. Siemens Healthineers Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 109. Siemens Healthineers Tumor Biomarker Testing Product Offered

Table 110. Siemens Healthineers Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 111. Siemens Healthineers Main Business

Table 112. Siemens Healthineers Latest Developments

Table 113. Quest Diagnostics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 114. Quest Diagnostics Tumor Biomarker Testing Product Offered

Table 115. Quest Diagnostics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 116. Quest Diagnostics Main Business

Table 117. Quest Diagnostics Latest Developments

Table 118. Labcorp Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 119. Labcorp Tumor Biomarker Testing Product Offered

Table 120. Labcorp Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 121. Labcorp Main Business

Table 122. Labcorp Latest Developments

Table 123. NeoGenomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

- Table 124. NeoGenomics Tumor Biomarker Testing Product Offered
- Table 125. NeoGenomics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 126. NeoGenomics Main Business
- Table 127. NeoGenomics Latest Developments
- Table 128. Exact Sciences Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
- Table 129. Exact Sciences Tumor Biomarker Testing Product Offered
- Table 130. Exact Sciences Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 131. Exact Sciences Main Business
- Table 132. Exact Sciences Latest Developments
- Table 133. Myriad Genetics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
- Table 134. Myriad Genetics Tumor Biomarker Testing Product Offered
- Table 135. Myriad Genetics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 136. Myriad Genetics Main Business
- Table 137. Myriad Genetics Latest Developments
- Table 138. Guardant Health Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
- Table 139. Guardant Health Tumor Biomarker Testing Product Offered
- Table 140. Guardant Health Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 141. Guardant Health Main Business
- Table 142. Guardant Health Latest Developments
- Table 143. Caris Life Sciences Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
- Table 144. Caris Life Sciences Tumor Biomarker Testing Product Offered
- Table 145. Caris Life Sciences Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 146. Caris Life Sciences Main Business
- Table 147. Caris Life Sciences Latest Developments
- Table 148. Tempus AI Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors
- Table 149. Tempus AI Tumor Biomarker Testing Product Offered
- Table 150. Tempus AI Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)
- Table 151. Tempus AI Main Business

Table 152. Tempus AI Latest Developments

Table 153. Natera Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 154. Natera Tumor Biomarker Testing Product Offered

Table 155. Natera Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 156. Natera Main Business

Table 157. Natera Latest Developments

Table 158. Personalis Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 159. Personalis Tumor Biomarker Testing Product Offered

Table 160. Personalis Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 161. Personalis Main Business

Table 162. Personalis Latest Developments

Table 163. Invivoscribe Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 164. Invivoscribe Tumor Biomarker Testing Product Offered

Table 165. Invivoscribe Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 166. Invivoscribe Main Business

Table 167. Invivoscribe Latest Developments

Table 168. Biocartis Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 169. Biocartis Tumor Biomarker Testing Product Offered

Table 170. Biocartis Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 171. Biocartis Main Business

Table 172. Biocartis Latest Developments

Table 173. Sysmex Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 174. Sysmex Tumor Biomarker Testing Product Offered

Table 175. Sysmex Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 176. Sysmex Main Business

Table 177. Sysmex Latest Developments

Table 178. Leica Biosystems Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 179. Leica Biosystems Tumor Biomarker Testing Product Offered

Table 180. Leica Biosystems Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 181. Leica Biosystems Main Business

Table 182. Leica Biosystems Latest Developments

Table 183. Cepheid Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 184. Cepheid Tumor Biomarker Testing Product Offered

Table 185. Cepheid Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 186. Cepheid Main Business

Table 187. Cepheid Latest Developments

Table 188. Menarini Silicon Biosystems Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 189. Menarini Silicon Biosystems Tumor Biomarker Testing Product Offered

Table 190. Menarini Silicon Biosystems Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 191. Menarini Silicon Biosystems Main Business

Table 192. Menarini Silicon Biosystems Latest Developments

Table 193. Veracyte Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 194. Veracyte Tumor Biomarker Testing Product Offered

Table 195. Veracyte Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 196. Veracyte Main Business

Table 197. Veracyte Latest Developments

Table 198. Castle Biosciences Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 199. Castle Biosciences Tumor Biomarker Testing Product Offered

Table 200. Castle Biosciences Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 201. Castle Biosciences Main Business

Table 202. Castle Biosciences Latest Developments

Table 203. OncoDNA Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 204. OncoDNA Tumor Biomarker Testing Product Offered

Table 205. OncoDNA Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 206. OncoDNA Main Business

Table 207. OncoDNA Latest Developments

Table 208. ACT Genomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 209. ACT Genomics Tumor Biomarker Testing Product Offered

Table 210. ACT Genomics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 211. ACT Genomics Main Business

Table 212. ACT Genomics Latest Developments

Table 213. GC Genome Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 214. GC Genome Tumor Biomarker Testing Product Offered

Table 215. GC Genome Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 216. GC Genome Main Business

Table 217. GC Genome Latest Developments

Table 218. Burning Rock Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 219. Burning Rock Tumor Biomarker Testing Product Offered

Table 220. Burning Rock Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 221. Burning Rock Main Business

Table 222. Burning Rock Latest Developments

Table 223. Amoy Diagnostics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 224. Amoy Diagnostics Tumor Biomarker Testing Product Offered

Table 225. Amoy Diagnostics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 226. Amoy Diagnostics Main Business

Table 227. Amoy Diagnostics Latest Developments

Table 228. Genetron Health Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 229. Genetron Health Tumor Biomarker Testing Product Offered

Table 230. Genetron Health Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 231. Genetron Health Main Business

Table 232. Genetron Health Latest Developments

Table 233. 3DMed Diagnostics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 234. 3DMed Diagnostics Tumor Biomarker Testing Product Offered

Table 235. 3DMed Diagnostics Tumor Biomarker Testing Revenue (\$ million), Gross

Margin and Market Share (2021-2026)

Table 236. 3DMed Diagnostics Main Business

Table 237. 3DMed Diagnostics Latest Developments

Table 238. Singlera Genomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 239. Singlera Genomics Tumor Biomarker Testing Product Offered

Table 240. Singlera Genomics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 241. Singlera Genomics Main Business

Table 242. Singlera Genomics Latest Developments

Table 243. BGI Genomics Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 244. BGI Genomics Tumor Biomarker Testing Product Offered

Table 245. BGI Genomics Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 246. BGI Genomics Main Business

Table 247. BGI Genomics Latest Developments

Table 248. Geneseeq Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 249. Geneseeq Tumor Biomarker Testing Product Offered

Table 250. Geneseeq Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 251. Geneseeq Main Business

Table 252. Geneseeq Latest Developments

Table 253. Genecast Details, Company Type, Tumor Biomarker Testing Area Served and Its Competitors

Table 254. Genecast Tumor Biomarker Testing Product Offered

Table 255. Genecast Tumor Biomarker Testing Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 256. Genecast Main Business

Table 257. Genecast Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Tumor Biomarker Testing Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Tumor Biomarker Testing Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Tumor Biomarker Testing Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Tumor Biomarker Testing Sales Market Share by Country/Region (2025)

Figure 8. Tumor Biomarker Testing Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Tumor Biomarker Testing Market Size Market Share by Type in 2025

Figure 10. Global Tumor Biomarker Testing Market Size Market Share by Sample Source in 2025

Figure 11. Global Tumor Biomarker Testing Market Size Market Share by Delivery Model in 2025

Figure 12. Global Tumor Biomarker Testing Market Size Market Share by Detection Technology in 2025

Figure 13. Tumor Biomarker Testing in Lung Cancer

Figure 14. Global Tumor Biomarker Testing Market: Lung Cancer (2021-2026) & (\$ millions)

Figure 15. Tumor Biomarker Testing in Breast Cancer

Figure 16. Global Tumor Biomarker Testing Market: Breast Cancer (2021-2026) & (\$ millions)

Figure 17. Tumor Biomarker Testing in Colorectal

Figure 18. Global Tumor Biomarker Testing Market: Colorectal (2021-2026) & (\$ millions)

Figure 19. Tumor Biomarker Testing in Prostate Cancer

Figure 20. Global Tumor Biomarker Testing Market: Prostate Cancer (2021-2026) & (\$ millions)

Figure 21. Tumor Biomarker Testing in Blood Cancer

Figure 22. Global Tumor Biomarker Testing Market: Blood Cancer (2021-2026) & (\$ millions)

Figure 23. Global Tumor Biomarker Testing Market Size Market Share by Application in 2025

Figure 24. Global Tumor Biomarker Testing Revenue Market Share by Player in 2025

Figure 25. Global Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)

Figure 26. Americas Tumor Biomarker Testing Market Size 2021-2026 (\$ millions)

Figure 27. APAC Tumor Biomarker Testing Market Size 2021-2026 (\$ millions)

Figure 28. Europe Tumor Biomarker Testing Market Size 2021-2026 (\$ millions)

Figure 29. Middle East & Africa Tumor Biomarker Testing Market Size 2021-2026 (\$ millions)

Figure 30. Americas Tumor Biomarker Testing Value Market Share by Country in 2025

Figure 31. United States Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 32. Canada Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 33. Mexico Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 34. Brazil Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 35. APAC Tumor Biomarker Testing Market Size Market Share by Region in 2025

Figure 36. APAC Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)

Figure 37. APAC Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)

Figure 38. China Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 39. Japan Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 40. South Korea Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 41. Southeast Asia Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 42. India Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 43. Australia Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 44. Europe Tumor Biomarker Testing Market Size Market Share by Country in 2025

Figure 45. Europe Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)

Figure 46. Europe Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)

Figure 47. Germany Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

Figure 48. France Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)

- Figure 49. UK Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 50. Italy Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 51. Russia Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 52. Middle East & Africa Tumor Biomarker Testing Market Size Market Share by Region (2021-2026)
- Figure 53. Middle East & Africa Tumor Biomarker Testing Market Size Market Share by Type (2021-2026)
- Figure 54. Middle East & Africa Tumor Biomarker Testing Market Size Market Share by Application (2021-2026)
- Figure 55. Egypt Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 56. South Africa Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 57. Israel Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 58. Turkey Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 59. GCC Countries Tumor Biomarker Testing Market Size Growth 2021-2026 (\$ millions)
- Figure 60. Americas Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 61. APAC Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 62. Europe Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 63. Middle East & Africa Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 64. United States Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 65. Canada Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 66. Mexico Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 67. Brazil Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 68. China Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 69. Japan Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 70. Korea Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 71. Southeast Asia Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 72. India Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 73. Australia Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 74. Germany Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 75. France Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 76. UK Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 77. Italy Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 78. Russia Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 79. Egypt Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 80. South Africa Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)
- Figure 81. Israel Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)

Figure 82. Turkey Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)

Figure 83. Global Tumor Biomarker Testing Market Size Market Share Forecast by Type (2027-2032)

Figure 84. Global Tumor Biomarker Testing Market Size Market Share Forecast by Application (2027-2032)

Figure 85. GCC Countries Tumor Biomarker Testing Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Tumor Biomarker Testing Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G85C07B3C702EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G85C07B3C702EN.html>